Skin Carcinoma — Variants & evidence · CancerIndex

Skin Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

13 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–13 of 13 evidence items (13 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR P753S1
Cetuximab + SirolimusCombination	Skin Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1089 72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy wi… (full text at CIViC) PMID 24934779 · Ganesan et al., 2016 · Open in CIViC	civic
PPARGC1A Fusion1
(diagnostic)	Skin Squamous Cell Carcinoma	Diagnostic	D	Supports Positive	2	submitted	EID10997 By transcriptome sequencing, they identified the fusion variant EGFR::PPARGC1A in around 30% (31 out of 102) of cutaneous squamous cell carcinoma (cSCC). They found that the lesions harboring the fusi… (full text at CIViC) PMID 28978917 · Egashira et al., 2017 · Open in CIViC	civic
ERBB2 Amplification1
Trastuzumab	Scrotal Paget DiseaseALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1693 A 71-year old male with metastatic extramammary Paget’s disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable di… (full text at CIViC) PMID 25692060 · Barth et al., 2015 · Open in CIViC	civic
HRAS G12D1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID3698 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
HRAS G13D1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	1	accepted	EID3851 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
HRAS G13V1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID4418 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
HRAS Q61K1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID3850 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
HRAS Q61L1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID3848 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
HRAS Q61R1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID3849 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
KMT2C Mutation1
(prognostic)	Skin Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	3	accepted	EID1696 Evaluation of 39 aggressive cutaneous squamous cell carcinomas revealed that tumors with a KMT2C mutation were 5x more likely to invade the bone (53% versus 10%; p=0.008). Patients with KMT2C mutatio… (full text at CIViC) PMID 25303977 · Pickering et al., 2014 · Open in CIViC	civic
KRAS G12C1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID3982 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
KRAS G12D1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID3961 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic
TP53 P278S1
Vemurafenib	Skin Squamous Cell Carcinoma	Predictive	C	Supports Resistance	—	submitted	EID4419 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic

Data updated 21 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.